Anti-angiogenic therapy in uveal melanoma

Developments in Ophthalmology

Volumn 49, Issue , 2012, Pages 117-136

  El Filali, Mariam ^a   Van Der Velden, Pieter A ^a   Luyten, Gregorius P M ^a   Jager, Martine J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925969795     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000329591     Document Type: Article

References (123)

1. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-153.
2. Papetti M, Herman IM: Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002;282:C947-C970.
3. Criscuolo GR, Merrill MJ, Oldfield EH: Further characterization of malignant glioma-derived vascular permeability factor. J Neurosurg 1988;69:254-262.
4. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
5. Karayiannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C, Karatzas G: Circulating VEGF levels in the serum of gastric cancer patients: Correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 2002; 236:37-42.
6. Celen O, Kahraman I, Yildirim E, Berberoglu U: Correlation of vascular endothelial growth factor (VEGF) and CEA with clinicopathological variables in colorectal cancer patients. Neoplasma 2004;51: 293-299.
7. Hayes AJ, Mostyn-Jones A, Koban MU, A'Hern R, Burton P, Thomas JM: Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br J Surg 2004;91:242-247.
8. Barak V, Pe'er J, Kalickman I, Frenkel S: VEGF as a biomarker for metastatic uveal melanoma in humans. Curr Eye Res 2011;36:386-390.
9. el Filali M, Missotten GS, Maat W, Ly LV, Luyten GP, van der Velden PA, Jager MJ: Regulation of VEGF-A in uveal melanoma. Invest Ophthalmol Vis Sci 2010;51:2329-2337.
10. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
11. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434.
12. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A: A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30:117-124.
13. Varker KA, Biber JE, Kefauver C, Jensen R, Lehman A, Young D, Wu H, Lesinski GB, Kendra K, Chen HX, Walker MJ, Carson WE 3rd: A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007;14:2367-2376.
14. Van CE, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ: Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27:2231-2237.
15. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-231.
16. Yang H, Jager MJ, Grossniklaus HE: Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Invest Ophthalmol Vis Sci 2010;51:2835-2842.
17. Foss AJ, Alexander RA, Jefferies LW, Hungerford JL, Harris AL, Lightman S: Microvessel count predicts survival in uveal melanoma. Cancer Res 1996;56: 2900-2903.
18. Lane AM, Egan KM, Yang J, Saornil MA, Alroy J, Albert D, Gragoudas ES: An evaluation of tumour vascularity as a prognostic indicator in uveal melanoma. Melanoma Res 1997;7:237-242.
19. Foss AJ, Alexander RA, Hungerford JL, Harris AL, Cree IA, Lightman S: Reassessment of the PAS patterns in uveal melanoma. Br J Ophthalmol 1997;81: 240-246.
20. Makitie T, Summanen P, Tarkkanen A, Kivela T: Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Invest Ophthalmol Vis Sci 1999;40:2471-2480.
21. Makitie T, Summanen P, Tarkkanen A, Kivela T: Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst 1999;91:359-367.
22. Folberg R, Hendrix MJ, Maniotis AJ: Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000; 156:361-381.
23. Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M, Sasaki H, Kasumi F, Yoshimoto M, Iwanaga T, Konishi F, Terada M, Wakasugi H: Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 2001;61:445-451.
24. Coupland SE, Campbell I, Damato B: Routes of extraocular extension of uveal melanoma: Risk factors and influence on survival probability. Ophthalmology 2008;115:1778-1785.
25. Ly LV, Odish OF, Wolff-Rouendaal D, Missotten GS, Luyten GP, Jager MJ: Intravascular presence of tumor cells as prognostic parameter in uveal melanoma: A 35-year survey. Invest Ophthalmol Vis Sci 2010;51:658-665.
26. Augsburger JJ, Correa ZM, Freire J, Brady LW: Long-term survival in choroidal and ciliary body melanoma after enucleation versus plaque radiation therapy. Ophthalmology 1998;105:1670-1678.
27. Kujala E, Makitie T, Kivela T: Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003;44:4651-4659.
28. Economou MA, All-Ericsson C, Bykov V, Girnita L, Bartolazzi A, Larsson O, Seregard S: Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: Intercorrelation and prognostic implications. Invest Ophthalmol Vis Sci 2005;46:4372-4375.
29. Baserga R: The insulin-like growth factor I receptor: A key to tumor growth? Cancer Res 1995;55:249-252.
30. Slomiany MG, Rosenzweig SA: IGF-1-induced VEGF and IGFBP-3 secretion correlates with increased HIF-1 alpha expression and activity in retinal pigment epithelial cell line D407. Invest Ophthalmol Vis Sci 2004;45:2838-2847.
31. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-410.
32. Handsley MM, Edwards DR: Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005;115:849-860.
33. Littlepage LE, Sternlicht MD, Rougier N, Phillips J, Gallo E, Yu Y, Williams K, Brenot A, Gordon JI, Werb Z: Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res 2010;70:2224-2234.
34. El Shabrawi Y, Ardjomand N, Radner H, Ardjomand N: MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma. J Pathol 2001;194:201-206.
35. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A, Normanno N: The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 2008;214:559-567.
36. Ferrara N: The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005;209-231.
37. Boyd SR, Tan D, Bunce C, Gittos A, Neale MH, Hungerford JL, Charnock-Jones S, Cree IA: Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: Identification of a potential therapeutic window. Br J Ophthalmol 2002;86:448-452.
38. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
39. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW: The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991;5:1806-1814.
40. Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, Ferrara N: Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptorselective VEGF variants by site-directed mutagenesis. J Biol Chem 1996;271:5638-5646.
41. Weigand M, Hantel P, Kreienberg R, Waltenberger J: Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 2005;8:197-204.
42. Ferrara N: Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9(suppl 1):2-10.
43. Vincenti V, Cassano C, Rocchi M, Persico G: Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996;93:1493-1495.
44. Prescher G, Bornfeld N, Becher R: Nonrandom chromosomal abnormalities in primary uveal melanoma. J Natl Cancer Inst 1990;82:1765-1769.
45. Naus NC, van Drunen E, de Klein A, Luyten GP, Paridaens DA, Alers JC, Ksander BR, Beverloo HB, Slater RM: Characterization of complex chromosomal abnormalities in uveal melanoma by fluorescence in situ hybridization, spectral karyotyping, and comparative genomic hybridization. Genes Chromosomes Cancer 2001;30:267-273.
46. Abdel-Rahman MH, Craig EL, Davidorf FH, Eng C: Expression of vascular endothelial growth factor in uveal melanoma is independent of 6p21-region copy number. Clin Cancer Res 2005;11:73-78.
47. White VA, Chambers JD, Courtright PD, Chang WY, Horsman DE: Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer 1998;83:354-359.
48. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845.
49. Wang GL, Semenza GL: Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-1237.
50. Mizukami Y, Kohgo Y, Chung DC: Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res 2007;13:5670-5674.
51. Verhoeff JJ, Stalpers LJ, Claes A, Hovinga KE, Musters GD, Peter VW, Richel DJ, Leenders WP, van Furth WR: Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma. Eur J Cancer 2009;45:3074-3080.
52. Shibuya M: Structure and function of VEGF/VEGFreceptor system involved in angiogenesis. Cell Struct Funct 2001;26:25-35.
53. Economou MA, Wu J, Vasilcanu D, Rosengren L, All-Ericsson C, van der Ploeg I, Menu E, Girnita L, Axelson M, Larsson O, Seregard S, Kvanta A: Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor. Invest Ophthalmol Vis Sci 2008;49:2620-2626.
54. Economou MA, Andersson S, Vasilcanu D, All-Ericsson C, Menu E, Girnita A, Girnita L, Axelson M, Seregard S, Larsson O: Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. Invest Ophthalmol Vis Sci 2008;49:2337-2342.
55. Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marme D: Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 1996;56:2299-2301.
56. Rankin EB, Rha J, Unger TL, Wu CH, Shutt HP, Johnson RS, Simon MC, Keith B, Haase VH: Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice. Oncogene 2008;27:5354-5358.
57. Haase VH, Glickman JN, Socolovsky M, Jaenisch R: Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci USA 2001;98:1583-1588.
58. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, Kerbel RS: Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995;55:4575-4580.
59. Maat W, el Filali M, Dirsk-Mulder A, Luyten GP, Gruis NA, Desjardins L, Boender P, Jager MJ, van der Velden PA: Episodic Src activation in uveal melanoma revealed by kinase activity profiling. Br J Cancer 2009;101:312-319.
60. Takahashi H, Shibuya M: The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005;109:227-241.
61. Bates DO, Harper SJ: Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol 2002;39:225-237.
62. Qi JH, Matsumoto T, Huang K, Olausson K, Christofferson R, Claesson-Welsh L: Phosphoinositide 3 kinase is critical for survival, mitogenesis and migration but not for differentiation of endothelial cells. Angiogenesis 1999;3:371-380.
63. Jager MJ, Ly LV, El Filali M, Madigan MC: Macrophages in uveal melanoma and in experimental ocular tumor models: Friends or foes? Prog Retin Eye Res 2011;30:129-146.
64. Volm M, Koomagi R, Mattern J, Stammler G: Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro. Anticancer Res 1997;17:99-103.
65. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, Dvorak HF: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993;53:4727-4735.
66. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP: Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 1996;56:2013-2016.
67. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO: Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29.
68. Ijland SA, Jager MJ, Heijdra BM, Westphal JR, Peek R: Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. Melanoma Res 1999;9:445-450.
69. Sheidow TG, Hooper PL, Crukley C, Young J, Heathcote JG: Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis. Br J Ophthalmol 2000;84:750-756.
70. Boyd SR, Tan DS, de Souza L, Neale MH, Myatt NE, Alexander RA, Robb M, Hungerford JL, Cree IA: Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth. Br J Ophthalmol 2002;86:440-447.
71. Missotten GS, Notting IC, Schlingemann RO, Zijlmans HJ, Lau C, Eilers PH, Keunen JE, Jager MJ: Vascular endothelial growth factor a in eyes with uveal melanoma. Arch Ophthalmol 2006;124:1428-1434.
72. Hayes AJ, Mostyn-Jones A, Koban MU, A'Hern R, Burton P, Thomas JM: Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br J Surg 2004;91:242-247.
73. Eskelin S, Pyrhonen S, Summanen P, Prause JU, Kivela T: Screening for metastatic malignant melanoma of the uvea revisited. Cancer 1999;85:1151-1159.
74. Kaiserman I, Amer R, Pe'er J: Liver function tests in metastatic uveal melanoma. Am J Ophthalmol 2004; 137:236-243.
75. Barak V, Frenkel S, Kalickman I, Maniotis AJ, Folberg R, Pe'er J: Serum markers to detect metastatic uveal melanoma. Anticancer Res 2007;27:1897-1900.
76. Missotten GS, Korse CM, van Dehn C, Linders TC, Keunen JE, Jager MJ, Bonfrer JM: S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests. Tumour Biol 2007;28:63-69.
77. Potgens AJ, Lubsen NH, van Altena MC, Schoenmakers JG, Ruiter DJ, de Waal RM: Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol 1995;146:197-209.
78. Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo KT, Manseau EJ, Dvorak HF: Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996;56:172-181.
79. Sahin A, Kiratli H, Soylemezoglu F, Tezel GG, Bilgic S, Saracbasi O: Expression of vascular endothelial growth factor-A, matrix metalloproteinase-9, and extravascular matrix patterns and their correlations with clinicopathologic parameters in posterior uveal melanomas. Jpn J Ophthalmol 2007;51:325-331.
80. Crosby MB, Yang H, Gao W, Zhang L, Grossniklaus HE: Serum vascular endothelial growth factor (VEGF) levels correlate with number and location of micrometastases in a murine model of uveal melanoma. Br J Ophthalmol 2011;95:112-117.
81. Land SC, Tee AR: Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 2007;282:20534-20543.
82. Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC: Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006;66:184-191.
83. Kenyon BM, Browne F, D'Amato RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997;64:971-978.
84. Kalas W, Gilpin S, Yu JL, May L, Krchnakova H, Bornstein P, Rak J: Restoration of thrombospondin 1 expression in tumor cells harbouring mutant ras oncogene by treatment with low doses of doxycycline. Biochem Biophys Res Commun 2003;310:109-114.
85. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311.
86. Lima BR, Schoenfield LR, Singh AD: The impact of intravitreal bevacizumab therapy on choroidal melanoma. Am J Ophthalmol 2011;151:323-328.
87. Melia BM, Abramson DH, Albert DM, Boldt HC, Earle JD, Hanson WF, Montague P, Moy CS, Schachat AP, Simpson ER, Straatsma BR, Vine AK, Weingeist TA: Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. 1. Visual acuity after 3 years COMS report No 16. Ophthalmology 2001;108:348-366.
88. Shields CL, Shields JA, Cater J, Gunduz K, Miyamoto C, Micaily B, Brady LW: Plaque radiotherapy for uveal melanoma: Long-term visual outcome in 1,106 consecutive patients. Arch Ophthalmol 2000;118: 1219-1228.
89. ener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, Schachat AP, Straatsma BR: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. 3. Initial mortality findings. COMS Report No 18. Arch Ophthalmol 2001;119:969-982.
90. Gragoudas ES, Lane AM, Munzenrider J, Egan KM, Li W: Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. Trans Am Ophthalmol Soc 2002;100:43-48.
91. Shields CL, Cater J, Shields JA, Chao A, Krema H, Materin M, Brady LW: Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: Tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol 2002;120:933-940.
92. Jampol LM, Moy CS, Murray TG, Reynolds SM, Albert DM, Schachat AP, Diddie KR, Engstrom RE Jr, Finger PT, Hovland KR, Joffe L, Olsen KR, Wells CG: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. 4. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report No 19. Ophthalmology 2002;109:2197-2206.
93. Archer DB, Gardiner TA: Ionizing radiation and the retina. Curr Opin Ophthalmol 1994;5:59-65.
94. Guyer DR, Mukai S, Egan KM, Seddon JM, Walsh SM, Gragoudas ES: Radiation maculopathy after proton beam irradiation for choroidal melanoma. Ophthalmology 1992;99:1278-1285.
95. Sia S, Harper C, McAllister I, Perry A: Iodine-I25 episcleral plaque therapy in uveal melanoma. Clin Experiment Ophthalmol 2000;28:409-413.
96. 125I plaque brachytherapy for ocular melanoma. Int J Radiat Oncol Biol Phys 2005;63:101-108.
97. Mason JO III, Albert MA Jr, Persaud TO, Vail RS: Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma. Retina 2007;27:903-907.
98. Finger PT: Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). Int J Radiat Oncol Biol Phys 2008;70:974-977.
99. Gupta A, Muecke JS: Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin). Retina 2008;28:964-968.
100. Querques G, Prascina F, Iaculli C, Delle NN: Intravitreal pegaptanib sodium (Macugen) for radiation retinopathy following episcleral plaque radiotherapy. Acta Ophthalmol 2008;86:700-701.
101. Narayanan R, Kuppermann BD, Jones C, Kirkpatrick P: Ranibizumab. Nat Rev Drug Discov 2006;5:815-816.
102. Finger PT, Chin KJ: Intravitreous ranibizumab (lucentis) for radiation maculopathy. Arch Ophthalmol 2010;128:249-252.
103. Fukasawa M, Korc M: Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res 2004; 10:3327-3332.
104. Augsburger JJ, Correa ZM, Shaikh AH: Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 2009;148:119-127.
105. Mangiameli DP, Blansfield JA, Kachala S, Lorang D, Schafer PH, Muller GW, Stirling DI, Libutti SK: Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. J Transl Med 2007;5:38.
106. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ, Ratain MJ: Sorafenib in advanced melanoma: A phase II randomised discontinuation trial analysis. Br J Cancer 2006;95:581-586.
107. Chow LQ, Eckhardt SG: Sunitinib: From rational design to clinical efficacy. J Clin Oncol 2007;25: 884-896.
108. Kerbel RS: Tumor angiogenesis. N Engl J Med 2008;358:2039-2049.
109. Ebos JM, Lee CR, Bogdanovic E, Alami J, Van Slyke P, Francia G, Xu P, Mutsaers AJ, Dumont DJ, Kerbel RS: Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 2008;68: 521-529.
110. Casanovas O, Hicklin DJ, Bergers G, Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309.
111. Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA: Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res 2006;66:9054-9064.
112. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, Song H, Vandenberg S, Johnson RS, Werb Z, Bergers G: HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008;13:206-220.
113. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN: Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008;26:271-278.
114. Bronkhorst IH, Ly LV, Jordanova ES, Vrolijk H, Versluis M, Luyten GP, Jager MJ: Detection of M2 macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci 2011;52:643-650.
115. D'Angelo G, Struman I, Martial J, Weiner RI: Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci USA 1995;92:6374-6378.
116. Parenti A, Morbidelli L, Cui XL, Douglas JG, Hood JD, Granger HJ, Ledda F, Ziche M: Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J Biol Chem 1998;273:4220-4226.
117. Shepard DR, Garcia JA: Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma. Expert Rev Anticancer Ther 2009;9:795-805.
118. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431-435.
119. Boehm S, Rothermundt C, Hess D, Joerger M: Antiangiogenic drugs in oncology: A focus on drug safety and the elderly -A mini-review. Gerontology 2010;56:303-309.
120. Ansari J, Glaholm J, McMenemin R, James ND, Hussain SA: Recent advances and future directions in the management of metastatic renal cell carcinoma. Anticancer Agents Med Chem 2010;10:225-235.
121. Lefevre G, Glotin AL, Calipel A, Mouriaux F, Tran T, Kherrouche Z, Maurage CA, Auclair C, Mascarelli F: Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. J Biol Chem 2004;279:31769-31779.
122. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
123. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res 2010;184:83-102.